| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3339883 | Allergologia et Immunopathologia | 2014 | 7 Pages |
Abstract
Profile of asthmatic patients treated with omalizumab predominantly corresponds to uncontrolled severe asthma cases, in accordance with SPC's indications. The results of the study suggest a favourable clinical course similar to that observed in other studies.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
J. Ancochea, T. Chivato, P. Casan, C. Picado, L. Herráez, J. Casafont,